The core activity of Accense is the acquisition, development and marketing of pharmaceutical products, in particular those abandoned by large pharmaceutical companies. The company focuses on reviving and marketing established, safe and effective medicines that are useful for public health. Products include Postafen, Agyrax and Navidoxine, which are distributed in various countries such as France, Scandinavia, Malta and the USA.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Commercialisation of Postafen, Agyrax and Navidoxine under different brands, with distribution in Europe and prescription or OTC status depending on the countries.
Acquisition and porting of pharmaceutical products
Acquisition of safe, effective pharmaceutical products, transfer and porting of the AMMs to Accense, with takeover of the meclozine-based specialty.
Pharmaceutical development and use expansion
Development of products through new indications, Rx-to-OTC status change, boosting via scientific medical information and targeted commercial development.
Research and selection of pharmaceutical products
Research on mature products that are useful for public health, well tolerated and neglected by large groups, as well as on innovative products with patient benefit.
International commercialisation and local regulatory management
Commercialisation by country, interface with health authorities, regulatory management, pharmacovigilance, medical affairs and relations with health authorities.
Knowledge
No knowledge articles yet
Once Accense S.A. has claimed this profile, we'll publish editorial articles and case studies here together.